SR-4370

SR-4370 is a **synthetic small molecule inhibitor of histone deacetylases (HDACs)**, with a strong preference for inhibiting HDAC3 (IC50 values in the low nanomolar range), and selectivity over other HDAC isoforms such as HDAC1, HDAC2, HDAC6, and HDAC8[1][4][3]. It has been experimentally studied as an **epigenetic modulator** for several indications: - In HIV-1 research, SR-4370 acts as a **latency reversing agent (LRA)**, efficiently reactivating latent HIV-1 without causing undue toxicity or activation of CD4+ T cells, suggesting utility for the "shock and kill" approach in HIV cure strategies[2][5]. - In Duchenne muscular dystrophy (DMD) models (e.g., zebrafish), SR-4370 ameliorates muscle lesions, increases muscle integrity, and extends lifespan by increasing histone acetylation, indicating possible therapeutic benefit for dystrophinopathies[3]. SR-4370 was originally developed by Scripps Florida Funding Corp.[7].

Brand names

SR-4370SR4370SR 4370

Other names

2',3'-difluoro-[1,1'-biphenyl]-4-carboxylic acid, 2-butylhydrazide